What is ropivacaine studying for pain relief in hip replacement?

Ropivacaine is being studied to see if it can reduce pain after primary total hip arthroplasty by blocking nerves around the hip capsule. This trial compares ropivacaine to a placebo to understand its effect on postoperative opioid use and pain. The study is sponsored by Diakonie-Klinikum Stuttgart.

Who may be eligible for this hip replacement clinical trial?

Adults aged 18 years or older who are scheduled for a cementless primary hip replacement via a minimally invasive anterolateral approach may be eligible. Participants should not regularly use opioids or have chronic pain conditions. Both men and women can participate. Please review eligibility criteria for more details.

Is there any cost to participate in this hip replacement clinical trial?

Study-related care, including the study drug or procedure and all trial visits, is provided at no cost. However, personal travel expenses may vary and are not guaranteed to be covered. Participants should plan accordingly.

Actively Recruiting

Phase Not Applicable

Age: 18Years +

All Genders

ID06557044

Effectiveness of Pericapsular Nerve Group PENG Block for Pain Relief in Adults Undergoing Primary Total Hip Replacement Surgery A Double-Blind, Randomized Controlled Study Comparing Ropivacaine and Saline

Led by Diakonie-Klinikum Stuttgart · Updated on 2024-08-16

110

Participants Needed

Research Sites

N/A

Total Duration

AI-Summary

What this Trial Is About

Researchers are evaluating the pain-relieving effects of the pericapsular nerve group PENG block during hip replacement surgery. This prospective, randomized, double-blind study compares two groups of patients undergoing primary total hip arthroplasty. Participants are assigned to receive either 20 ml of ropivacaine 0.5% or 20 ml of a saline solution as a placebo to assess the impact on postoperative pain management. The study involves two treatment groups one receiving the PENG block with ropivacaine, a local anesthetic, and the other receiving a placebo injection of physiological saline. Both treatments are administered during the hip implant procedure, which uses a minimally invasive anterolateral approach with a specific implant system. The trial is designed to maintain blinding and randomization to fairly compare the effects. Participants will be monitored for opioid use within the first hour after recovery room arrival, along with total opioid consumption, pain levels, nausea, vomiting, and overall recovery until the evening of the second day after surgery. The study tracks these outcomes closely to understand the efficacy of the PENG block. The total duration of involvement includes the surgical procedure and postoperative observation up to two days after surgery.

CONDITIONS

Brief Title

The Analgesic Efficacy of Pericapsular Nerve Group (PENG) Block in Patients Undergoing Primary Total Hip Arthoplasty:

Who Can Participate

Age: 18Years +

All Genders

Eligibility Criteria

You may qualify if you...

Planned cementless hip total endoprosthesis operation for primary osteoarthritis using a minimally invasive anterolateral approach with the identical implant system (Taperloc stem, Plamafit cup)
Patient capable of giving consent
Informed consent has been obtained
Age over 18 years

You will not qualify if you...

Refusal to participate in the study
Regular use of opioids
Known chronic pain symptoms
Infections in the area of the puncture site
Contraindication to ropivacaine
Contraindication to metamizole
Contraindication to postoperative analgesia with diclofenac
Secondary osteoarthritis with deformities such as high-grade dysplasia, trauma-related conditions, or childhood hip diseases
Spinopelvic imbalance or spinal canal stenosis
Previous operations on the hip or pelvis

Research Team

Rainer Meierhenrich, Prof. Dr.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here